Patient-derived organoids
Patient-derived organoids are miniature 3D versions of a patient's tumour grown in the lab.
Living biobanks of organoids (HUB, Broad) preserve genotype and drug response. Used for drug screening, CRISPR studies, and increasingly co-cultured with immune cells for immunotherapy testing.
Schematic · not to scale
3D mini-tumours in matrix
How it works
Stem-cell-driven 3D culture in extracellular matrix with defined growth factors.
Strengths
- Fidelity to patient tumour
- Scalable
Limitations
- Lacks vasculature and full microenvironment
Latest papers
topLatest papers · live from Europe PMC
Query for this technology: (TITLE:"patient-derived organoid" OR ABSTRACT:"patient-derived organoid" OR TITLE:"patient-derived organoids" OR ABSTRACT:"patient-derived organoids" OR TITLE:"tumor organoid" OR ABSTRACT:"tumor organoid"). Results are unfiltered search hits about Patient-derived organoids, not a curated reading list.
fronts
1technologies
4companies
4institutions
9Atrium Health Wake Forest Baptist Comprehensive Cancer CenterCold Spring Harbor LaboratoryKeio University HospitalLustgarten FoundationPrincess Máxima Center for Pediatric OncologyTongji Hospital, Huazhong University of Science and TechnologyUMC Utrecht Cancer CenterWalter and Eliza Hall Institute of Medical ResearchWellcome Sanger Institute
terms
4roadmaps
1ideas
36A bone marrow niche on a chip to study human dormancyA drug screen that only rewards killing sleeping cancer cellsA funded organoid and PDX panel as the go/no-go gate before IND-enabling moneyA public atlas of drug-pair responses across a thousand patient-derived organoidsA synthetic lethality map for every cancer driver in every tissue contextA universal material transfer agreement with a thirty-day defaultAn independent replication institute that re-tests key preclinical cancer findings before trialsAn open engine that ranks every drug pair by predicted synergy before anyone runs a trialAn open model bank for the rare tumours nobody has models forAn open model of every cancer cell state, built from perturbation atlasesAn open organoid bank for cancers too rare to have modelsAutomated combination discovery: patient-sample screens feeding Bayesian platform trialsBarcode patient-derived tumours to watch which clones win under each drugBuild a human model of the barrier that guards the brain fluidBuild laboratory models of the organs cancer spreads toDigital twins for treatment selection, validated by predicting before observingGrow blood-borne tumour cells to test drugs on the cells that actually spreadGrow each trial patient's tumour as organoids to decide which platform arm opens nextGrow models from tumour cells in the blood when a biopsy is impossibleGrow tumour organoids together with the patient's own immune cellsHold organoid drug tests to the same standard as a diagnostic testKeep a freshly removed tumour alive on a pump and test drugs in itLinked human organ chips to predict side effects before people are dosedMake in vivo metastasis screens a required step in drug discoveryPatient-derived organoids to pick ADC payloadsPick the laboratory model that matches the patient, not the one to handRun the mouse or organoid trial at the same time as the human trialScore every model system on how well it predicted real trial resultsScore every preclinical model by how often it predicted the clinical resultSelf-driving laboratories that run the cancer biology hypothesis loop autonomouslySet aside 3% of grant budgets to replicate findings before translationShared reference organoid and PDX panels that every lab can test againstTest drugs on freshly cut slices of the patient's own tumourTest drugs on the patient's own cancer cells when there is no trial to joinTumour-on-a-chip with blood flow to test whether big drugs actually get inUse patient organoids to check a cell therapy will work before infusing it